Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies

Source: Benzinga ·

Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies

On Monday, Roche Holdings AG (OTC:RHHBY) announced that the U.S. Food and Drug Administration approved two treatments across its breast cancer and immunology portfolios, clearing Wilserdly for advanced breast cancer and Gazyva/Gazyvaro for chronic kidney disease. FDA Approves Ora

Read the full story at Benzinga

Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.

More from the world desk